Optimer Pharmaceuticals (Nasdaq: OPTR) is expected to report Q1 earnings around May 3. Here's what Wall Street wants to see:

The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Optimer Pharmaceuticals's revenues will expand 48.1% and EPS will remain in the red.

The average estimate for revenue is $21.3 million. On the bottom line, the average EPS estimate is -$0.46.

Revenue details
Last quarter, Optimer Pharmaceuticals booked revenue of $19.5 million. GAAP reported sales were 70% lower than the prior-year quarter's $64.6 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
Last quarter, EPS came in at $0.02. GAAP EPS of $0.02 for Q4 were 93% lower than the prior-year quarter's $0.28 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
For the preceding quarter, gross margin was 84.5%, 900 basis points worse than the prior-year quarter. Operating margin was -155.4%, much worse than the prior-year quarter. Net margin was 5.1%, much worse than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $99.7 million. The average EPS estimate is -$1.83.

Investor sentiment
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 106 members out of 146 rating the stock outperform, and 40 members rating it underperform. Among 45 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 30 give Optimer Pharmaceuticals a green thumbs-up, and 15 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Optimer Pharmaceuticals is outperform, with an average price target of $16.56.